The stock has a 36-month beta value of 1.77. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TWST is 55.59M, and at present, short sellers hold a 16.23% of that float. On November 19, 2024, the average trading volume of TWST was 716.86K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TWST) stock’s latest price update
Twist Bioscience Corp (NASDAQ: TWST)’s stock price has increased by 12.31 compared to its previous closing price of 36.89. However, the company has seen a -12.37% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-18 that Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for several years even as revenues rise. The company does have a solid balance sheet and north of $1.2 billion in net loss carry forwards.
TWST’s Market Performance
Twist Bioscience Corp (TWST) has seen a -12.37% fall in stock performance for the week, with a -11.72% decline in the past month and a -3.45% plunge in the past quarter. The volatility ratio for the week is 8.75%, and the volatility levels for the past 30 days are at 5.78% for TWST. The simple moving average for the last 20 days is -2.50% for TWST stock, with a simple moving average of -2.94% for the last 200 days.
Analysts’ Opinion of TWST
Many brokerage firms have already submitted their reports for TWST stocks, with Guggenheim repeating the rating for TWST by listing it as a “Buy.” The predicted price for TWST in the upcoming period, according to Guggenheim is $53 based on the research report published on June 04, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see TWST reach a price target of $45, previously predicting the price at $25. The rating they have provided for TWST stocks is “Buy” according to the report published on January 17th, 2024.
Berenberg gave a rating of “Buy” to TWST, setting the target price at $27 in the report published on September 27th of the previous year.
TWST Trading at -5.80% from the 50-Day Moving Average
After a stumble in the market that brought TWST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.97% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 8.75%, as shares sank -8.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.19% upper at present.
During the last 5 trading sessions, TWST fell by -12.37%, which changed the moving average for the period of 200-days by +13.23% in comparison to the 20-day moving average, which settled at $42.49. In addition, Twist Bioscience Corp saw 12.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TWST starting from CHESS ROBERT, who sale 3,600 shares at the price of $47.26 back on Nov 11 ’24. After this action, CHESS ROBERT now owns 21,641 shares of Twist Bioscience Corp, valued at $170,139 using the latest closing price.
Cho Dennis, the of Twist Bioscience Corp, sale 1,507 shares at $48.00 during a trade that took place back on Nov 11 ’24, which means that Cho Dennis is holding 91,163 shares at $72,333 based on the most recent closing price.
Stock Fundamentals for TWST
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.43 for the gross margin
The net margin for Twist Bioscience Corp stands at -0.67. The total capital return value is set at -0.41. Equity return is now at value -38.08, with -30.02 for asset returns.
Based on Twist Bioscience Corp (TWST), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 7886.86.
Currently, EBITDA for the company is -220.83 million with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of 7.3. The receivables turnover for the company is 8.97for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.88.
Conclusion
To sum up, Twist Bioscience Corp (TWST) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
